Drug Profile


Alternative Names: allo-APZ2-CVU; allo-APZ2-DFU; ALLO-APZ2-PAOD; APZ2

Latest Information Update: 09 Oct 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator RHEACELL
  • Class Cell therapies; Skin disorder therapies; Stem cell therapies; Vascular disorder therapies
  • Mechanism of Action ATP-binding cassette transporter modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Phase I/II Peripheral arterial occlusive disorders; Varicose ulcer
  • Suspended Diabetic foot ulcer

Most Recent Events

  • 29 Sep 2017 Suspended - Phase-I/II for Diabetic neuropathic ulcer in Germany (Topical) prior to September 2017 (287698; EudraCT2017-000233-31)
  • 21 Aug 2017 Phase-I/II clinical trials in Peripheral arterial occlusive disorders (In adults, In the elderly) in Germany (IM) (EudraCT2017-000235-14)
  • 07 Aug 2017 Phase-I/II clinical trials in Diabetic foot ulcer in Germany (Topical) (EudraCT2017-000234-57)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top